Itau Unibanco Holding S.A. Has $62,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Itau Unibanco Holding S.A. lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 19.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 473 shares of the life sciences company’s stock after selling 111 shares during the period. Itau Unibanco Holding S.A.’s holdings in Illumina were worth $62,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Industrial Alliance Investment Management Inc. acquired a new position in Illumina during the 2nd quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV increased its holdings in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares in the last quarter. Private Trust Co. NA raised its holdings in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new position in Illumina during the second quarter worth $63,000. Finally, Focused Wealth Management Inc bought a new position in shares of Illumina in the third quarter valued at $63,000. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ILMN shares. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $120.00 to $154.00 in a research report on Friday, August 16th. Royal Bank of Canada boosted their price objective on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. Barclays upped their price target on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Robert W. Baird raised their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $140.60 on Wednesday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a fifty day simple moving average of $142.42 and a two-hundred day simple moving average of $126.45. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The firm has a market cap of $22.30 billion, a price-to-earnings ratio of -14.12 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the company earned $0.33 EPS. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. Analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.